The preventive transient treatment with ACH2.0 drugs, discussed in the present section, can potentially be combined with targeting the initial causes of unconventional AD or the unconventional stimuli activating the AβPP-independent iAβ production pathway. The gene discussed is APP; the disease is Alzheimer disease.